Yu, Dongyin
Amgen (United States)
4 papers on CoChatORCID 0009-0009-6804-285X
Most cited papers
- Verified
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 290
- Verified
The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 152
- Verified
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 82
- Verified
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Saiki, A. Y., Caenepeel, S., Yu, D., Lofgren, J. A., Osgood, T., Robertson, R., Canon, J., Su, C., Jones, A., Zhao, X., et al. (2014) · Oncotarget
Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
Cited by 55
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free